Literature DB >> 18362281

Dementia and survival in Parkinson disease: a 12-year population study.

T C Buter1, A van den Hout, F E Matthews, J P Larsen, C Brayne, D Aarsland.   

Abstract

BACKGROUND: The risk for dementia in Parkinson disease (PD) is high, with important clinical consequences for patients with PD. However, the absolute risk of dementia and how it affects survival in PD are not known. Such questions are important for patients, their families, and service providers but require long-term studies.
METHODS: This study is a prospective longitudinal cohort study with patients from a prevalence study of PD in Norway. Patients were reassessed 4, 8, 9, 10, 11, and 12 years after prevalence day. A dementia diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, criteria was based on a semistructured caregiver interview, cognitive rating scales, and neuropsychological tests. Progression from PD to PD with dementia and death was modeled using a continuous-time three-state irreversible Markov model.
RESULTS: A total of 233 PD patients were included, and 140 patients (60%, 95% CI 54% to 66%) had developed dementia by the end of the study period. The cumulative incidence of dementia steadily increases with age and duration of PD and, conditional on survival, increases to 80% to 90% by age 90 years. Women live with PD longer than men and spend more years with dementia. At age 70 years, a man with PD but no dementia has a life expectancy of 8 years, of which 5 years would be expected to be dementia free and 3 years would be expected to be with dementia.
CONCLUSION: Dementia is a key part of survival in Parkinson disease and must be planned for in services for this condition.

Entities:  

Mesh:

Year:  2008        PMID: 18362281     DOI: 10.1212/01.wnl.0000306632.43729.24

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  117 in total

1.  Sentence processing in Lewy body spectrum disorder: the role of working memory.

Authors:  Rachel G Gross; Corey T McMillan; Keerthi Chandrasekaran; Michael Dreyfuss; Sharon Ash; Brian Avants; Philip Cook; Peachie Moore; David J Libon; Andrew Siderowf; Murray Grossman
Journal:  Brain Cogn       Date:  2012-01-02       Impact factor: 2.310

Review 2.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

3.  The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.

Authors:  Sharon Ash; Sharon X Xie; Rachel Goldmann Gross; Michael Dreyfuss; Ashley Boller; Emily Camp; Brianna Morgan; Jessica O'Shea; Murray Grossman
Journal:  Neuropsychology       Date:  2012-02-06       Impact factor: 3.295

4.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

Review 5.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

Review 6.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

7.  Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

Authors:  James B Leverenz; G Stennis Watson; Jane Shofer; Cyrus P Zabetian; Jing Zhang; Thomas J Montine
Journal:  Parkinsonism Relat Disord       Date:  2010-11-01       Impact factor: 4.891

Review 8.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

9.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

10.  MEG resting state functional connectivity in Parkinson's disease related dementia.

Authors:  J L W Bosboom; D Stoffers; E Ch Wolters; C J Stam; H W Berendse
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.